Doximity (DOCS) faces limited clarity on the near-term path of revenue and margins, as well as execution risks tied to its shift into an artificial intelligence-powered platform for healthcare professionals, BofA Securities said Monday.
The digital platform, which dominates the pharmaceutical advertising targeting physicians, is "making the right strategic investments" as it competes with AI-focused entities such as OpenAI and OpenEvidence, BofA analyst Allen Lutz said in a note to clients. Doximity's offerings include a new a new AI assistant for physicians called DoxGPT.
"Given the deep pockets of these peers and the fact that top 20 pharma already spends significantly with Doximity, we have some concerns around (Doximity's) ability to grow its current allocations as well as successfully compete for AI dollars," Lutz said.
The brokerage downgraded its rating on the Doximity stock to underperform from buy and reduced the price target to $20 from $38. "While shares are inexpensive, we see downside risk to consensus over the next few years," Lutz wrote.
The company's shares were down 2.7% in Monday afternoon trade. The stock has lost 54% in value so far this year.
"We anticipate Doximity's emerging investment cycle to go on for multiple years and could include more significant investments than investors currently appreciate," Lutz said. "With current margins still near 50%, we think it is not unreasonable to expect Doximity to spend more money for a longer period of time, which could weigh on margins."
The company may need to lower its prices to support sales, according to the note. "Together, we see structural pressure to Doximity's industry-leading margin profile," Lutz said.
BofA lowered its 2027 and 2028 revenue outlook for Doximity.
"We anticipate pharma manufacturers will continue to diversify spend across AI competitors in the coming years, which is likely to limit Doximity's share gains," Lutz said. "This leaves Doximity more reliant on (healthcare professional) pharma market growth and the trajectory of pharma ad-spend allocation."
Price: $20.23, Change: $-0.65, Percent Change: -3.11%



